beyond pink team
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us
 If you are Breast Cancer Survivor and  you would like to contribute your story to our Newsletter, 
​please send us a message here.
DOWNLOAD Current NewsletteR

Categories

All
Advocacy
Bone Health
Breast Density
Breast Disease
Caregivers
COVID 19
COVID-19
Emotional Support
Environment
Exercise
Fatigue
Financial
Gender
Genetic Testing
Grief
High Risk
Hormone Replacement Therapy
Ignite
Implants
Intimacy After Cancer
LGBTQ
Lymphedema
Mammography
Meditation
Men
Mental Health
Metastasis
MRI
NBCC
Nutrition
Obesity
Pain
Pregnancy
Prevention
Radiation
Reconstruction
Reduce Risk
Rehabilitation
Screening
Sex
Side Effects
Support Groups
Surgery
Survivor
Survivorship
Treatment
Vaccine
Yoga
Young Women

Archives

January 2023
October 2022
July 2022
April 2022
January 2022
October 2021
July 2021
April 2021
January 2021
October 2020
July 2020
April 2020
January 2020
October 2019
July 2019
April 2019
January 2019
October 2018
July 2018
April 2018
January 2018
October 2017
July 2017
April 2017
January 2017
October 2016
July 2016
April 2016
January 2016
October 2015
July 2015
April 2015
January 2015
October 2014
July 2014
April 2014
January 2014
October 2013
July 2013
April 2013
January 2013
October 2012
July 2012
April 2012
January 2012
October 2011
July 2011
April 2011
January 2011
October 2010
July 2010
April 2010
January 2010
October 2009
July 2009
April 2009
January 2009
October 2008
July 2008
April 2008
January 2008
October 2007
July 2007
April 2007
January 2007
October 2006
July 2006
April 2006
January 2006
October 2005
July 2005
April 2005
January 2005
October 2004
July 2004
April 2004
January 2004

onco type dx

4/1/2008

0 Comments

 
Picture
By Mukund Nadipuram, MD
​
Today the treatment plan for women with breast cancer is tailored to each patient depending on certain test results. Tumors are examined by a pathologist to determine the type of breast cancer it is, as well as newer tests that could be helpful in tailoring treatment options.

One of the tests for identifying the specific type of breast cancer a woman has is whether the tumor is Estrogen Receptor(ER) positive or not. If a tumor is ER-positive, that means the tumor growth is fed or accelerated by estrogen. In many cases, a drug is used to suppress the estrogen production, (estrogen blockade) thereby preventing growth of the cancer cells. Other deciding factors for treatment include tumor size and axillary lymph node involvement. Approximately 25,000 women were diagnosed with ER-positive breast cancer with negative axillary lymph nodes (no sign of spreading) in 2005. This type of breast cancer accounts for half of all breast cancers. Treatment guidelines recommend chemotherapy for all women whose tumors are 1 cm or larger, and for smaller tumors if some of the tissue tests indicate a less favorable long-term outcome.

Approximately 80% are treatable with ―hormonal therapy‖, such as the drugs Tamoxifen or Arimidex. Adding chemotherapy reduces the risk of recurrence; however the absolute benefit for the individual patient is small and ranges from 2 to 5%. Therefore, the vast majority of patients taking chemotherapy for ER-positive breast cancer with negative lymph nodes may be over treated, and may have benefited from hormone therapy alone.

Treatment recommendations have generally been based on several predictive features. There are tools that are currently available such as "adjuvant online", providing decision making help for clinicians and patients. Although such tools helps somewhat to make informed decisions, when faced with the choice, many patients and clinicians error on the side of over-treatment because of imprecise nature of predicting treatment benefit.

What is OncoType DX ?
A number of molecular diagnostic tests and prognostic molecular signatures have been evaluated which are also commercially available now.

OncoType DX is: 1. A currently standardized multigene, (21 genes/16 tumor genes, and 5 reference gene), study by molecular technique. 2. It is done utilizing the tumor tissue that is removed from the breast. 3. It more reliably predicts prognosis than standard clinical criteria in patients with ER-positive, node-negative breast cancer. 4. Its performance has been validated in a large population 
based study.

How is OncoType DX resulted?
The assay (or analysis) includes 16 tumor genes and 5 reference genes with the result expressed as a computed recurrence score. Less than 11 is a low risk. Between 11 and 25 is intermediate risk. Greater than 25 is high risk.

A National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial indicated that only patients with an elevated recurrence score derived benefit from the chemotherapy. It is clear that patients with very low recurrence score do very well with hormonal therapy alone, and patients with very high recurrence score benefit from chemotherapy, but, there is still uncertainty as to whether chemotherapy is necessary for patients who have mid-range, (11 to 25 recurrence score), and who meet established clinical criteria for "adjuvant chemotherapy". Hence there is currently an ongoing clinical trial (TAILORx) to address this exact question.

OncoType DX represents a major step forward into the era of personalized medicine for breast cancer. By integrating a molecular diagnostic test into clinical decision making, patients and clinicians will be able to make more informed choices regarding the most appropriate treatment options. 

​

Read Full Newsletter
0 Comments

A SURVIVOR'S STORY: SCARS, MARKS AND TATTOOS

4/1/2008

0 Comments

 

by Debra (DJ) Corson

Seven was never my lucky number. I should have known it would be bad news when I was scheduled to learn the results of my biopsy for breast cancer on 7- 17-07.

To share my story, I have selected excerpts from my journal and ―updates‖ sent to friends and family.

Surgery
Our son asked me how I was doing as I was leaving for surgery. I said, ―I feel like this is the first day of feeling bad for months.‖ He said, “Mom, I believe this is the first day of you getting better.”

Chemo
Saturday—not great, but OK. Sunday—definitely not good. I better take something for this nausea thing…hum, I have three different meds for nausea, which one? This one can make you dizzy, this one is likely to cause a huge headache, this one makes you drowsy. Monday—THIS is BAD! Must not have taken the right thing for nausea … Food repulses me. I can’t watch TV because it is full of food commercials. I just want to get into a dark room, crawl into a ball, and sleep. It’s important for me to focus on the chemo as helping me get to better (not making me sick).

Losing my hair
It is always so windy at Hawkeye (Community College). When I walk across campus, I take $20. If my wig blows off, the accumulative effects of the chemo have me so worn down, I know I can’t run after it. With the 20 bucks, I’m hoping some passing student will run after it for the reward money.

From where we draw strength I’ve been playing the song Stand, by Rascal Flatts repeatedly. It helps me stay strong. The outpouring of support from friends is both overwhelming and humbling. All I can do is appreciate with my whole heart what has been done for me. Then, pay if forward because I can never pay it all back.

Finishing treatment
A celebration—my hair is growing back! I feel like a CHIA pet--just put some fertilized mud on my head, water it, and watch it grow! I’ll be glad when I have enough eyelashes to use mascara again. Wouldn’t you know, the wild hair on my chin is already back! I am in charge of my attitude, what I contribute to life, and how I treat my body. I am NOT in control of the outcome of this illness. I can hope for a miracle, but I cannot make one happen. And I am not a failure if one doesn’t happen.

My husband, who is in law enforcement, often talks about SMTs--Scars, Marks, and Tattoos. ​In his work, they are important for identification purposes. Breast cancer surgery, chemotherapy, and radiation gives survivors some SMTs of their own, but they aren’t just physical.

Our physical, emotional, and spiritual scars, marks, and tattoos serve as an important part of our identification: who are we today, and who we are becoming. 

​
Read Full Newsletter
0 Comments

CONTACT US

Beyond Pink TEAM
c/o Jeanne Olson, Treasurer
1407 Asbury Lane
Waterloo, IA 50701
​beyondpinkteam@gmail.com
(319) 239-3706
©2020 Beyond Pink TEAM
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us